Condition: GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor Disease · Sponsor: RayzeBio, Inc.
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.
This description comes directly from the study's public registry record.
RayzeBio Clinical Trials · +1 619 657 0057 · clinicaltrials@rayzebio.com
Always discuss trial participation with your own doctor first.
| Research Facility | Phoenix, Arizona, United States | Active Not Recruiting |
| Research Facility | Duarte, California, United States | Completed |
| Research Facility | Irvine, California, United States | Recruiting |
| Research Facility | Los Angeles, California, United States | Active Not Recruiting |
| Research Facility | Palo Alto, California, United States | Active Not Recruiting |
| Research Facility | San Francisco, California, United States | Active Not Recruiting |
| Research Facility | New Haven, Connecticut, United States | Active Not Recruiting |
| Research Facility | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Research Facility | Jacksonville, Florida, United States | Active Not Recruiting |
| Research Facility | Miami, Florida, United States | Recruiting |
| Research Facility | Tampa, Florida, United States | Recruiting |
| Research Facility | Atlanta, Georgia, United States | Active Not Recruiting |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05477576